Lyra Therapeutics, Inc. Common Stock
LYRALyra Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for chronic nasal and sinus conditions. The company leverages a proprietary delivery platform to address unmet medical needs in ENT (ear, nose, and throat) disorders, aiming to provide minimally invasive treatments with long-lasting effects.
Company News
Lyra Therapeutics reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210, a treatment for chronic rhinosinusitis. The trial met its primary and key secondary endpoints, demonstrating statistically significant improvements in symptoms compared to sham control.
Lyra Therapeutics plans to present positive 52-week results from the Extension Stage of the ENLIGHTEN 1 Phase 3 study for its lead product candidate LYR-210 in treating chronic rhinosinusitis. The results support LYR-210's favorable safety profile and durable symptom control.
Lyra Therapeutics has fully enrolled the pivotal Phase 3 ENLIGHTEN 2 trial of its drug candidate LYR-210 for the treatment of chronic rhinosinusitis. Topline results are expected in Q2 2025.
Lyra Therapeutics, a clinical-stage biotechnology company, will present results from its Phase 3 ENLIGHTEN 1 study for LYR-210 and Phase 2 BEACON study for LYR-220 at the upcoming ARS and AAO-HNS annual meetings.
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures.
